Minerva Surgical, Inc.
6
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
100%
6 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Symphion® System In-Office Study
Role: lead
Registry Study of Genesys HTA for Treatment of Menorrhagia
Role: lead
Minerva Pivotal Study to Evaluate Safety and Efficacy of the Aurora Endometrial Ablation System Compared to Hysteroscopic Rollerball Ablation
Role: lead
A Multi-Center, Single Arm Clinical Study of the Safety and Efficacy of the AURORA™ Endometrial Ablation System
Role: lead
A Single Arm Clinical Study of the Safety and Efficacy of the AURORA™ Endometrial Ablation System
Role: lead
A Two-Phase Clinical Study of the Minerva AURORA Ablation System
Role: lead
All 6 trials loaded